Site Reference ID/Investigator# 8087
Gainesville, Florida, 32608, United States
NCT Number: NCT00681525
The objective of this study is to evaluate the potential PK interaction between ABT-335, atorvastatin 80 mg and ezetimibe 10 mg when administered concurrently.
Looking for future studies?
Notify Me18 year–55 year
All sexes
Interventional
Phase 1
Gainesville, Florida, 32608, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
One ABT-335 135 mg capsule QD for 10 days
Other names: fenofibric acid
One 80 mg tablet of atorvastatin QD for 10 days
Other names: atovastatin
One ezetimibe 10 mg tablet QD for 10 days
Time frame: Study duration approximately 62 days
Looking for future studies?
Notify MeAbbott
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05328778
Pharmacokinetics
Guangzhou, Guangdong, China
View Trial DetailsNCT06665555
Healthy Volunteers, Pharmacokinetics
Phoenix, Arizona, United States
View Trial DetailsNCT07771309
Absorption of Omega-3, Omega-3 Fatty Acids
Copenhagen, Denmark
View Trial DetailsNCT07422285
Healthy Participants, Pharmacokinetics
Springfield, Missouri, United States
View Trial Details